within Pharmacolibrary.Drugs.ATC.S;

model S01AD06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.18 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 15 / 1000000,
    adminCount     = 1,
    Vd             = 0.0005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Vidarabine (adenine arabinoside, Ara-A) is an antiviral compound used primarily in the past for the treatment of herpes simplex virus (HSV) infections, especially in immunocompromised patients and for herpes simplex encephalitis. It has largely been replaced by acyclovir and other antivirals and is not commonly used today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients following intravenous administration.</p><h4>References</h4><ol><li><p>Ghobadi, A, et al., &amp; Strati, P (2025). Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. <i>Lancet (London, England)</i> 405(10473) 127–136. DOI:<a href=&quot;https://doi.org/10.1016/S0140-6736(24)02462-0&quot;>10.1016/S0140-6736(24)02462-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39798981/&quot;>https://pubmed.ncbi.nlm.nih.gov/39798981</a></p></li><li><p>Kikuchi, T, et al., &amp; Okamoto, S (2021). Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine. <i>International journal of hematology</i> 113(1) 128–133. DOI:<a href=&quot;https://doi.org/10.1007/s12185-020-02990-y&quot;>10.1007/s12185-020-02990-y</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32886279/&quot;>https://pubmed.ncbi.nlm.nih.gov/32886279</a></p></li><li><p>Kuo, GM, et al., &amp; Burstein, AH (2001). Fludarabine pharmacokinetics after subcutaneous and intravenous administration in patients with lupus nephritis. <i>Pharmacotherapy</i> 21(5) 528–533. DOI:<a href=&quot;https://doi.org/10.1592/phco.21.6.528.34549&quot;>10.1592/phco.21.6.528.34549</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11349741/&quot;>https://pubmed.ncbi.nlm.nih.gov/11349741</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end S01AD06;
